Title: Cost-effectiveness of Fluticasone Propionate/Salmeterol (250/50mcg) Compared to Salmeterol (50mcg)<br>Author: Christopher Blanchette, Director, CPOR, Lovelace Respiratory Research Institute, PO Box 760, Davidson, NC, 28036, United States of America, cblanchette@lrri.org<br>Coauthor(s): Harris Silver, Hans Petersen, Meaghan St. Charles<br>Year: 2008<br>Abstract: Bootstrapping methods were assessed to provide population-based parameter estimates for a cost-effectiveness analysis of Fluticasone Propionate/Salmeterol 250/50mcg (FSC) compared to Salmeterol 50mcg (SAL) from a trial based economic analysis using incremental cost-effectiveness ratios (ICER).